Jakarta, cartitleloans Indonesia
–
Russia
Make a big breakthrough by finding a vaccine for cancer, entromix.
Based on the initial trial, this vaccine has a 100 percent efficacy level.
Enteromix test results show that patients experience tumor shrinkage and no serious side effects.
At present the enteromix vaccine is waiting for the Ministry of Health’s final approval before use or available to the public.
Entromix was developed using the same MRNA technology as the COVID-19 vaccine.This vaccination is also designed to train the immune system in recognizing and eradicating cancer cells.
The vaccine is said to be a safer and more sophisticated alternative solution than traditional medicine such as chemotherapy, as quoted
NDTV
.
If the vaccine is tested on a larger and tighter scale, enteromix can mark a new era of cancer treatment: effective and minimal side effects.
The initial target of the vaccine is to prevent colorectal or intestinal cancer which is one of the leading causes of death worldwide.
How is enteromix developed?
Enteromix is a research collaboration between Russian National Medical Research Radiology Center and Engelhardt Molecular Biology Institute.
This vaccine utilizes MRNA technology, similar to a platform that allows the development of the COVID-19 vaccine quickly, to produce a special immune response to cancer cells.
What is different from other cancer vaccines?
Each enteromix dose is adjusted to the genomic tumor of individuals.This is different from other vaccines that follow one size strategy for all.
Enteromix has two main innovations namely vaccine design and MRNA platform.
Related to design, each vaccine is made based on the genetic arrangement of individual tumors, increasing specificity, and immune involvement.
As for the MRNA platform, it means that it allows rapid development and scalability, and is easily adapted for various types of cancer.
The combination places enteromix on the frontline of therapeutic vaccine, which has the potential to overcome the long-term challenges in immunology-oncology.
Although it seems promising, the success of the initial trials does not guarantee long -term efficacy, not to mention faced with logistical challenges such as production and distribution of personalized MRNA vaccine.
(Jesus/BAC)
[Gambas: cartitleloans video]
Read More: Air Force Air Force Natural Accident While Landing at Oksibil Papua Airport
Read More: Minister of Karding After Viral with Azis Wellang: I am responsible
